Challenges of Implementing Regulated AI in Drug Development
The FDA’s recent rollout of the internal AI tool, Elsa, aims to address the challenges of regulatory document review, but experts warn that creating effective regulated AI is highly complex. Erez Kaminski, CEO of Ketryx, suggests that a neuro-symbolic approach, combining neural networks and rule-based AI, may be essential for managing the intricate demands of regulatory environments.